Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 9/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | SCN1A | P35498 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17325884 | 0.94 | CHRM2 (0.38) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL17325882 | 0.93 | CHRM2 (0.48) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL23992705 | 0.88 | CHRM2 (0.43) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL23395145 | 0.87 | LMNA (0.46) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL17325883 | 0.86 | CHRM2 (0.36) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL17325885 | 0.84 | CHRM2 (0.35) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL18882758 | 0.83 | CHRM2 (0.42) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL807035 | 0.81 | MMP8 (0.41) | CHRM1LMNATSHRMMP8ALDH1A1 | |
| SCHEMBL17325957 | 0.81 | LMNA (0.42) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| SCHEMBL10124341 | 0.80 | CHRM1 (0.43) | CHRM2CHRM1CHRM3CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11723990-B2 | Library of pH responsive polymers and nanoprobes thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-15 | — | — | US | disclosed |
| US-20200087451-A1 | DUAL MODALITY UPS NANOPROBES FOR TUMOR ACIDOSIS IMAGING | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2020-03-19 | — | — | US | disclosed |
| US-20170143852-A1 | LIBRARY OF PH RESPONSIVE POLYMERS AND NANOPROBES THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2017-05-25 | — | — | US | disclosed |
| WO-2015188157-A1 | LIBRARY OF PH RESPONSIVE POLYMERS AND NANOPROBES THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087451-A1 | DUAL MODALITY UPS NANOPROBES FOR TUMOR ACIDOSIS IMAGING | VHL, CASR, CA2 | CHRM2 2873/4885CHRM1 3070/4885CHRM3 3889/4885 |
| US-20170143852-A1 | LIBRARY OF PH RESPONSIVE POLYMERS AND NANOPROBES THEREOF | MSN, CD44, CD47 | CHRM2 4022/4885CHRM1 4328/4885CHRM3 3699/4885 |
| US-11723990-B2 | Library of pH responsive polymers and nanoprobes thereof | MSN, CD44, CD47 | CHRM2 4022/4885CHRM1 4328/4885CHRM3 3699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.